These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19862681)

  • 1. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
    Yin W; Karyagina EV; Lundberg AS; Greenblatt DJ; Lister-James J
    Biopharm Drug Dispos; 2010 Jan; 31(1):72-81. PubMed ID: 19862681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
    Foran JM; Oscier D; Orchard J; Johnson SA; Tighe M; Cullen MH; de Takats PG; Kraus C; Klein M; Lister TA
    J Clin Oncol; 1999 May; 17(5):1574-9. PubMed ID: 10334546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
    Malspeis L; Grever MR; Staubus AE; Young D
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure.
    Kielstein JT; Stadler M; Czock D; Keller F; Hertenstein B; Radermacher J
    Eur J Haematol; 2005 Jun; 74(6):533-4. PubMed ID: 15876260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bioavailability of oral fludarabine phosphate is unaffected by food.
    Oscier D; Orchard JA; Culligan D; Cunningham D; Johnson S; Parker A; Klein M; Gieschen H
    Hematol J; 2001; 2(5):316-21. PubMed ID: 11920267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and clinical pharmacology of fludarabine.
    Gandhi V; Plunkett W
    Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
    Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
    J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
    Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.
    Lichtman SM; Etcubanas E; Budman DR; Eisenberg P; Zervos G; D'Amico P; O'Mara V; Musgrave K; Cascella P; Melikian A; Hinderling PH; Ferrer JM; Williams GJ
    Cancer Invest; 2002; 20(7-8):904-13. PubMed ID: 12449721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
    Long-Boyle JR; Green KG; Brunstein CG; Cao Q; Rogosheske J; Weisdorf DJ; Miller JS; Wagner JE; McGlave PB; Jacobson PA
    Bone Marrow Transplant; 2011 Jan; 46(1):20-6. PubMed ID: 20383215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes.
    Fraternale A; Rossi L; Magnani M
    Biochim Biophys Acta; 1996 Oct; 1291(2):149-54. PubMed ID: 8898876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
    Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK
    J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of nelarabine in indolent leukemias.
    Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
    J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
    Gandhi V; Huang P; Chapman AJ; Chen F; Plunkett W
    Clin Cancer Res; 1997 Aug; 3(8):1347-55. PubMed ID: 9815818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
    Schleyer E; Braess J; Ramsauer B; Unterhalt M; Kaufmann C; Wilde S; Schüssler M; Hiddemann W
    Leukemia; 1995 Jun; 9(6):1085-90. PubMed ID: 7596174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z; Grasela DM; Krishna G
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.